We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Cyberknife Radiosurgery and Quality of Life

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: July 15, 2010
Last Update Posted: July 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Stanford University
The purpose of this study is to look at pain control and QOL improvement after treatment with CK Radiosurgery for spinal metastases.

Bone Cancer Central Nervous System Cancer

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Cyberknife Radiosurgery and Quality of Life

Resource links provided by NLM:

Further study details as provided by Stanford University:

Enrollment: 15
Study Start Date: July 2010
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient must have cancer metastases to the spine. They may have had previous surgical or not surgical treatments. Benign tumors will not be assessed.

Inclusion Criteria:

  • Patients with a spinal metastasis who will be treated with Cyberknife radiosurgery.
  • There are no age or gender restrictions.
  • There are no life expectancy restrictions.
  • Karnofsky Performance Status greater than 40.
  • Negative pregnancy test or clinically assessed as not pregnant.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients with benign tumors will not be included (neurofibromas, schwannomas, etc.)
  • Other investigational medications or treatments will be noted, but will not preclude inclusion.
  • Pregnant or nursing patients will be not be included in the study due to radiation exposure.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01163539

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Steven Daniel Chang Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01163539     History of Changes
Other Study ID Numbers: SPN0002
SU-07092010-6499 ( Other Identifier: Stanford University )
First Submitted: July 14, 2010
First Posted: July 15, 2010
Last Update Posted: July 1, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Bone Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Nervous System Diseases